scholarly journals Histone Deacetylase Inhibitors as Therapeutic Agents for Cancer Therapy: Drug Metabolism and Pharmacokinetic Properties

10.5772/27799 ◽  
2011 ◽  
Author(s):  
Ethirajulu Kantharaj ◽  
Ramesh Jayaram
Keyword(s):  
Cancer Therapy ◽  
Drug Metabolism ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitors ◽  
Therapeutic Agents ◽  
Pharmacokinetic Properties

scholarly journals Histone Deacetylase Inhibitors: Synthesis of Tetrapeptide Analogue SAHA/TPX

2011 ◽  
Vol 8 (s1) ◽  
pp. S79-S84
Author(s):  
Lynda Ekou ◽  
Tchirioua Ekou ◽  
Isabelle Opalinski ◽  
Jean Pierre Gesson
Keyword(s):  
Clinical Trial ◽  
Cancer Therapy ◽  
Phase I ◽  
Histone Deacetylase ◽  
Hydroxamic Acid ◽  
Histone Deacetylase Inhibitors ◽  
Hdac Inhibitors ◽  
Growth Arrest ◽  
Suberoylanilide Hydroxamic Acid ◽  
Specific Inhibitors

The inhibition of HDAC (histone deacetylase) activity by specific inhibitors induces growth arrest, differentiation and apoptosis of transformed or several cancer cells. Some of these inhibitors are in clinical trial at phase I or phase II. The discovery and development of specific HDAC inhibitors are helpful for cancer therapy. In this paper we describe the synthesis of simple inhibitorBhybrid analogue suberoylanilide hydroxamic acid (SAHA), trapoxinB(TPX B) in as little as five steps. This compound is interesting lead for the design of potent inhibitors of histone deacetylase.

Histone Deacetylase Inhibitors: Emerging Anticancer Therapeutic Agents?

2005 ◽  
Vol 7 ◽  
pp. S19-S30 ◽  
Author(s):  
Rebecca Kristeleit ◽  
Peter Fong ◽  
G. Wynne Aherne ◽  
Johann de Bono
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitors ◽  
Therapeutic Agents

scholarly journals The Effect of Organoselenium Compounds on Histone Deacetylase Inhibition and Their Potential for Cancer Therapy

2021 ◽  
Vol 22 (23) ◽  
pp. 12952
Author(s):  
Theolan Adimulam ◽  
Thilona Arumugam ◽  
Ashmika Foolchand ◽  
Terisha Ghazi ◽  
Anil A. Chuturgoon
Keyword(s):  
Cancer Therapy ◽  
Histone Deacetylase ◽  
Gene Transcription ◽  
Histone Deacetylase Inhibitors ◽  
Cancer Therapeutics ◽  
Epigenetic Changes ◽  
Organoselenium Compounds ◽  
Histone Proteins ◽  
Acetylation Status ◽  
Natural And Synthetic

Genetic and epigenetic changes alter gene expression, contributing to cancer. Epigenetic changes in cancer arise from alterations in DNA and histone modifications that lead to tumour suppressor gene silencing and the activation of oncogenes. The acetylation status of histones and non-histone proteins are determined by the histone deacetylases and histone acetyltransferases that control gene transcription. Organoselenium compounds have become promising contenders in cancer therapeutics. Apart from their anti-oxidative effects, several natural and synthetic organoselenium compounds and metabolites act as histone deacetylase inhibitors, which influence the acetylation status of histones and non-histone proteins, altering gene transcription. This review aims to summarise the effect of natural and synthetic organoselenium compounds on histone and non-histone protein acetylation/deacetylation in cancer therapy.

Histone Deacetylase Inhibitors as Potential Therapeutic Agents for the Treatment of Malignant Mesothelioma

2013 ◽  
Vol 13 (3) ◽  
pp. 476-482
Author(s):  
Patroklos Katafygiotis ◽  
Constantinos Giaginis ◽  
Efstratios Patsouris ◽  
Stamatios Theocharis
Keyword(s):  
Histone Deacetylase ◽  
Malignant Mesothelioma ◽  
Histone Deacetylase Inhibitors ◽  
Therapeutic Agents
Sign in / Sign up

Export Citation Format

Share Document